ETON Eton Pharmaceuticals Inc.

7.9
-0.02  -0%
Previous Close 7.92
Open 8.34
Price To Book 7.25
Market Cap 139260631
Shares 17,627,928
Volume 111,223
Short Ratio
Av. Daily Volume 35,506

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA decision due May 2019 or July 2019.
EM-100
Allergic conjunctivitis
Phase 3 trial planned.
ET-102
Multiple sclerosis
NDA to be filed in 2019.
DS-100
Intractable pain
Rolling NDA filed March 14, 2019.
DS-200
Nutritional deficiencies
NDA filed.
DS-300
Nutritional deficiencies
PDUFA date October 21, 2019.
ET-202
Injectable hospital product
Bridging study data due 3Q 2019.
EM-103
Hypothyroidism
NDA filing due 3Q 2019.
ET-203
Injectable hospital product
Trial to be initiated 2Q 2019.
EM-104
Neurological indication

Latest News

  1. Eton Pharmaceuticals to Present at 20th Annual B. Riley FBR Investor Conference
  2. Eton Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress
  3. Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
  4. Eton Pharmaceuticals to Report First Quarter 2019 Financial Results on Tuesday, May 7, 2019
  5. Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Business Progress
  6. Eton Pharmaceuticals Submits New Drug Application for DS-200
  7. Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
  8. Eton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference
  9. The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
  10. Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies
  11. Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
  12. The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug
  13. Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104
  14. Eton Pharmaceuticals Reports Third Quarter Results and Business Update
  15. Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™
  16. Eton Pharmaceuticals Announces Pricing of Initial Public Offering
  17. IPO Outlook For The Week: Banks And Biotechs